Oncology

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Oncology #Pathology #Preclinical #RNA #Target validation #Toxicology #Translational #Translational chemistry

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics By Dr William E. Fogler Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Patent Law #PCR #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

High Throughput Screening in Academia – Drug discovery initiatives at the University of Kansas

High Throughput Screening in Academia - Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in developing tool molecules… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Bioengineering #Business #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Lead discovery #Lead optimisation #Oncology #Pharmokinetics #Preclinical #Screening #System biology #Systems biology #Therapeutics

Prediction versus Attrition in Drug Discovery & Development

Prediction versus Attrition in Drug Discovery & Development By Professor Malcolm Young The research-intensive part of the pharmaceutical industry is facing unusual commercial difficulties, whose elements are now well-known. A substantial number of very valuable drugs have gone, or are about to go, off patent; too few good new premium… Read More

#Archive

#Biochemistry #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Oncology #Preclinical #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Transcending Proteasome Inhibition for the Treatment of Cancer

Transcending Proteasome Inhibition for the Treatment of Cancer By Dr Mark Rolfe Healthy cellular function requires a carefully controlled balance between protein synthesis and protein degradation, a process known as protein homeostasis. The major intracellular pathway for controlling protein degradation is the ubiquitin proteasome system (UPS). Specific pharmacological inhibition of… Read More

#Archive

#Analysis #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Isotope labelling #Lead discovery #Oncology #PCR #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation #Therapeutics #Toxicology

Screening the Human Kinome – Expectations Met or Promises Pending?

Screening the Human Kinome - Expectations Met or Promises Pending? By Dr Richard M. Eglen Protein kinases are important targets in drug discovery programmes aimed at treating cancer, autoimmune disorders, diabetes and neurological disorders. Novel information on kinase biology is opening up other approaches in the design of selective inhibitors… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Imaging #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #System biology #Systems biology #Target validation

The Potential of Molecular Imaging for Drug Discovery & Development

The Potential of Molecular Imaging for Drug Discovery & Development By Dr Ken Rubenstein By combining cutting-edge biomedical research with the time-proven ability to visualise the unseen, the rapidly emerging field of molecular imaging promises to open new vistas for a wide range of individuals, from basic researchers to scientists… Read More

#Archive

#Animal models #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Immunology #Lead discovery #Oncology #Regulatory #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Advances in Antibody Therapy – A promising new approach to how we treat cancer

Advances in Antibody Therapy - A promising new approach to how we treat cancer By Dr Patrick A Baeuerle Antibodies available today for cancer treatment, while effective, are typically used in combination with standard therapies because their activity as monotherapy is limited. Currently, four conventional antibody products dominate the oncology… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Immunology #In Silico Biology #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Progress in Systems-Based Analysis of Cellular Signalling

Progress in Systems-Based Analysis of Cellular Signalling By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates these attempts at therapeutic intervention, resulting in high failure rates due to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Oncology #Regulatory #RNA #Toxicology

The Role of Thorough QT Testing in Managing Drug Development

The Role of Thorough QT Testing in Managing Drug Development By Dr William S. Wheeler With few exceptions, all compounds being submitted to the Food and Drug Administration (FDA) for approval in the United States will require an assessment of QT prolongation, either by a standard Thorough QT/QTc study, or… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #Sequencing #Stem cells #System biology #Systems biology

21st Century Vaccines – A Development Renaissance

21st Century Vaccines - A Development Renaissance By Dr Jeff Stoddard, Charles Drucker and Dr Nigel Brown Human beings have benefited from vaccines for more than two centuries. From eradicating some of the deadliest diseases to nearly eliminating a host of others, including polio, measles, mumps and tetanus - vaccines… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Stem cells #Target validation

How Non-invasive Visible Light Imaging Can Change Drug Discovery

How Non-invasive Visible Light Imaging Can Change Drug Discovery Dr Peter Lassota and Dr Anjani Shah In the past decade, non-invasive visible light imaging gained acceptance not only as a valuable research tool, but also as a means of evaluating new compounds for efficacy and pharmacodynamic properties in drug discovery. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Theranostics #Therapeutics #Toxicology

Industry Strategies on Theranostics: Need for structural alignment

Industry Strategies on Theranostics: Need for structural alignment Dr Rutger O. van Merkerk and Dr Wouter P.C. Boon Theranostics is said to change the way patients will manage their disease. Such a change assumes that diagnostics and therapeutics become increasingly linked based on genetic information. Companies that adhere to this… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Molecular medicine #Oncology #Preclinical #Regulatory #RNA #Screening #Stem cells #Toxicology #Translational #Translational chemistry

Reshaping the Landscape of Cancer Drug Discovery and Development

Reshaping the Landscape of Cancer Drug Discovery and Development By Dr Paolo Paoletti The landscape of cancer drug discovery and development is shifting, adjusting and reshaping itself in response to the huge rush of scientific knowledge which has come to the fore over the past few decades. In collaboration with… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #Orphan drugs #Pathology #PCR #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Personalised Medicine – Innovation and empowerment or exuberant hyperbole?

Personalised Medicine - Technological innovation and patient empowerment or exuberant hyperbole? By Adam W. Culbertson, Dr Stephen J. Valentine and Dr Stephen Naylor The current paradigm of modern healthcare focuses on patient symptoms, subsequent diagnosis and corresponding treatment of the specific disease(s). Escalating healthcare costs and a trial and error… Read More

#Archive

#ADME / Tox #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Imaging #Lead discovery #Molecular medicine #Oncology #Pathology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Positron Emission Tomography (PET) – Shining a light on human disease

By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in reducing the attrition rates in… Read More

#Archive

#Academic #Analysis #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Genomics #High Content Screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Patent Law #Preclinical #Regulatory #RNA #System biology #Systems biology #Target validation #Therapeutics #Toxicology

India – Global pharmaceutical R&D powerhouse or contract research workshop?

India - Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality. Globalisation of drug discovery may provide such an opportunity,… Read More

#Archive